Drug Profile
Research programme: fetal haemoglobin stimulants - OSI Pharmaceuticals
Latest Information Update: 10 Jul 2001
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals
- Class Small molecules
- Mechanism of Action Fetal haemoglobin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Sickle cell anaemia; Thalassaemia
Most Recent Events
- 10 Jul 2001 No-Development-Reported for Sickle cell anaemia in USA (Unknown route)
- 10 Jul 2001 No-Development-Reported for Thalassaemia in USA (Unknown route)
- 28 May 1998 New profile